gauchers disease - Viral Trends
Sanofi SNY announced that a late-stage study, evaluating venglustat, an investigational oral glucosylceramide synthase inhibitor (GCSi), in patients aged 12 years and older with type 3 Gaucher disease ... Medical Xpress: Improving the recipe for gene therapy: New treatment for Gaucher disease shows promise Gregory and Deborah Macres from California lost their son, Gregory, in 1997, when he was just 4 years old. Little Gregory had a severe form of a rare genetic disorder called Gaucher disease and died ...
Understanding the Context
Improving the recipe for gene therapy: New treatment for Gaucher disease shows promise Monthly Prescribing Reference: Venglustat Improves Neurological Symptoms in Type 3 Gaucher Disease Venglustat significantly improved neurological symptoms in patients with type 3 Gaucher disease compared with enzyme replacement therapy. Venglustat, an investigational glucosylceramide (GL-1) ... What is Gaucher Disease?Gaucher Disease is a rare inherited disorder that impairs the body’s ability to break down a type of fat (glucocerebroside), resulting in fat buildup in the liver, spleen, and ... Radiography and other imaging allow doctors to assess the progress of Gaucher disease, including in people who don’t have any symptoms yet.
Image Gallery
Key Insights
It’s an important tool in guiding treatment decisions.